Citi Starts Dicerna Pharmaceuticals (DRNA) at Buy
Tweet
Share
E-mailGet Alerts DRNA Hot Sheet
Price: $38.22 --0%
Rating Summary:
5 Buy, 8 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 6 | Down: 10 | New: 22
Rating Summary:
5 Buy, 8 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 6 | Down: 10 | New: 22
Join SI Premium – FREE
Citi analyst Robyn Karnauskas initiates coverage on Dicerna Pharmaceuticals (NASDAQ: DRNA) with a Buy rating and a price target of $27.00.
For an analyst ratings summary and ratings history on Dicerna Pharmaceuticals click here. For more ratings news on Dicerna Pharmaceuticals click here.
Shares of Dicerna Pharmaceuticals closed at $15.43 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Barclays Starts Centrus Energy Corp. (LEU) at Equalweight
- TD Cowen Starts Freenome Inc. (FRNM) at Buy
- LifeSci Capital Starts Obsidian Therapeutics (OBX) at Outperform
Create E-mail Alert Related Categories
New CoverageRelated Entities
CitiSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
